{"id":6473,"date":"2023-04-21T21:38:00","date_gmt":"2023-04-21T21:38:00","guid":{"rendered":"https:\/\/bostonsp.com\/?p=6473"},"modified":"2023-07-21T21:58:34","modified_gmt":"2023-07-21T21:58:34","slug":"changes-in-hematologic-lab-measures-observed-in-patients-with-paroxysmal-nocturnal-hemoglobinuria-treated-with-c5-inhibitors-ravulizumab-and-eculizumab-real-world-evidence-from-a-us-based-emr-networ","status":"publish","type":"post","link":"https:\/\/bostonsp.com\/index.php\/2023\/04\/21\/changes-in-hematologic-lab-measures-observed-in-patients-with-paroxysmal-nocturnal-hemoglobinuria-treated-with-c5-inhibitors-ravulizumab-and-eculizumab-real-world-evidence-from-a-us-based-emr-networ\/","title":{"rendered":"Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network"},"content":{"rendered":"<p>Fishman, J., Kuranz, S., Yeh, M. M., Brzozowski, K., &amp; Chen, H. (2023). Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network. Hematology Reports, 15(2), 266-282. <a href=\"https:\/\/doi.org\/10.3390\/hematolrep15020027\" rel=\"nofollow\">https:\/\/doi.org\/10.3390\/hematolrep15020027<\/a><\/p>\n<p><strong><a href=\"https:\/\/www.mdpi.com\/2038-8330\/15\/2\/27\">View article<\/a><\/strong><\/p>\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<h4>Abstract<\/h4>\n<p>Paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired hematologic disorder, can be treated with C5 inhibitors (C5i) such as eculizumab or ravulizumab. This retrospective study is the first to describe real-world treatment patterns and changes in hematologic PNH-monitoring laboratory tests among C5i-treated US patients. Data were extracted from TriNetX Dataworks Network and included patients with a PNH diagnosis between 1 January 2010, and 20 August 2021. Patients were stratified into three cohorts based on their C5i usage: eculizumab, ravulizumab (prior eculizumab), and ravulizumab (eculizumab na\u00efve). Hematological markers (hemoglobin [Hb], lactate dehydrogenase [LDH], and absolute reticulocyte count [ARC]) and relevant clinical events (e.g., breakthrough hemolysis [BTH], complement-amplifying conditions [CAC], thrombosis, infection, and all-cause mortality) were captured any time within 12 months post-index treatment. Of the 143 (eculizumab), 43 (ravulizumab, prior eculizumab), and 33 (ravulizumab, eculizumab na\u00efve) patients, mean age across cohorts was 42\u201351 years, 55\u201361% were female, 63\u201373% were White, and 33\u201340% had aplastic anemia. Among all cohorts 12 months post-C5i treatment, 50\u201382% remained anemic, 8\u201332% required \u22651 transfusion, and 13\u201359% had BTH, of which 33%-54% had CACs. Additionally, thrombosis was seen in 7\u201315% of patients, infection in 20\u201325%, and mortality in 1\u20137%. These findings suggest many C5i-treated patients experience suboptimal disease control.<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p>Fishman, J., Kuranz, S., Yeh, M. M., Brzozowski, K., &amp; Chen, H. (2023). Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network. Hematology Reports, 15(2), 266-282. <a href=\"https:\/\/doi.org\/10.3390\/hematolrep15020027\" rel=\"nofollow\">https:\/\/doi.org\/10.3390\/hematolrep15020027<\/a> View article Abstract Paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":6476,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_eb_attr":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[9],"tags":[101,89,98,100,99],"class_list":["post-6473","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publications","tag-anemia","tag-hematology","tag-paroxysmal-nocturnal-hemoglobinuria","tag-rare-disease","tag-real-world-evidence"],"acf":[],"aioseo_notices":[],"jetpack_featured_media_url":"https:\/\/bostonsp.com\/wp-content\/uploads\/2023\/07\/Hematology-Reports.png","_links":{"self":[{"href":"https:\/\/bostonsp.com\/index.php\/wp-json\/wp\/v2\/posts\/6473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bostonsp.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bostonsp.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bostonsp.com\/index.php\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/bostonsp.com\/index.php\/wp-json\/wp\/v2\/comments?post=6473"}],"version-history":[{"count":3,"href":"https:\/\/bostonsp.com\/index.php\/wp-json\/wp\/v2\/posts\/6473\/revisions"}],"predecessor-version":[{"id":6477,"href":"https:\/\/bostonsp.com\/index.php\/wp-json\/wp\/v2\/posts\/6473\/revisions\/6477"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bostonsp.com\/index.php\/wp-json\/wp\/v2\/media\/6476"}],"wp:attachment":[{"href":"https:\/\/bostonsp.com\/index.php\/wp-json\/wp\/v2\/media?parent=6473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bostonsp.com\/index.php\/wp-json\/wp\/v2\/categories?post=6473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bostonsp.com\/index.php\/wp-json\/wp\/v2\/tags?post=6473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}